Table 3. . Patient- and caregiver-reported hours needed per treatment session and hours needed per month to manage aHUS.

Survey item	Eculizumab	Ravulizumab	p-value
Adult patient response	(n = 50)	(n = 50)
Time needed per treatment session, h   n†   Mean (SD)	49 3.5 (2.5)	48 3.2 (2.3)	.1886
Time needed per month to manage aHUS, h   n†   Mean (SD)	49 5.4 (6.7)	49 2.8 (4.4)	.0014

Caregiver response	(n = 16)	(n = 16)
Caregiver time needed per treatment session, h   Mean (SD)	6.3 (3.8)	4.4 (3.2)	.1063
Caregiver time needed per month to manage aHUS, h   Mean (SD)	3.3 (6.2)	1.7 (3.5)	.3203
Patient time needed per treatment session, h   Mean (SD)	5.3 (3.5)	4.9 (2.9)	.7193
Patient time needed per month to manage aHUS, h   Mean (SD)	2.9 (6.1)	1.7 (3.5)	.4369

^†Values that were clear outliers (possible misunderstanding of the question/response requirement) were removed.

Time (h) needed per treatment session included time taken to travel for/receive treatment. Time (h) needed per month to manage aHUS excluded time needed to receive treatment. The p-value compares the proportion of paired responses between eculizumab and ravulizumab using paired t-tests.

aHUS: Atypical hemolytic uremic syndrome; SD: Standard deviation.